Insmed Incorporated (NASDAQ:INSM) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lessened its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 1.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,210,187 shares of the biopharmaceutical company's stock after selling 16,539 shares during the quarter. Loomis Sayles & Co. L P owned 0.68% of Insmed worth $88,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in Insmed by 15,915.2% during the first quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company's stock worth $600,000 after buying an additional 21,963 shares during the period. Vanguard Group Inc. increased its stake in Insmed by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company's stock valued at $393,636,000 after purchasing an additional 383,714 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Insmed during the first quarter worth $33,000. Kennedy Capital Management LLC purchased a new stake in Insmed during the first quarter worth $267,000. Finally, Comerica Bank grew its holdings in Insmed by 3,984.1% in the first quarter. Comerica Bank now owns 49,540 shares of the biopharmaceutical company's stock valued at $1,344,000 after purchasing an additional 48,327 shares during the last quarter.

Insmed Trading Up 1.3 %

INSM stock traded up $0.94 on Monday, hitting $74.09. 1,675,779 shares of the company were exchanged, compared to its average volume of 2,240,910. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $13.25 billion, a price-to-earnings ratio of -13.18 and a beta of 1.12. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The business's fifty day moving average is $72.04 and its two-hundred day moving average is $66.60.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The company's revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.10) earnings per share. As a group, research analysts forecast that Insmed Incorporated will post -5.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on INSM shares. Stifel Nicolaus boosted their price objective on shares of Insmed from $74.00 to $88.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. JPMorgan Chase & Co. upped their price target on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a report on Friday. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. Truist Financial reaffirmed a "buy" rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, TD Cowen raised their price target on Insmed from $75.00 to $98.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $83.67.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 27,871 shares of the business's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares of the company's stock, valued at approximately $5,045,093.60. The trade was a 29.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the business's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. The trade was a 11.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is currently owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.